In fact, there are suggestions that ARBs might be beneficial in COVID-19 (2), as SARS-CoV-2 causes ACE2 downregulation slowing the Ang II conversion to the vasodilatory (2), anti-inflammatory and anti-atherosclerotic Ang 1-7 (16–18), while the use of ARBs would be beneficial by blocking the excessive Ang II AT1R-mediated Ang II activation, upregulating ACE2 activity, and increasing Ang 1-7 levels. The gene discussed is ANGPT1; the disease is COVID-19.